Earlier this year, the administration’s proposal to sharply cut National Institutes of Health funding prompted swift bipartisan opposition. Critics argue that undermining medical research—particularly in fields like Alzheimer’s and obesity—puts urgently needed treatments at risk and worsens the potential impact of MFN pricing on drug innovation.

Texans are poised to decide whether to allocate $3 billion to dementia and Alzheimer’s research. A personal account from a former librarian, once famed for her quick mind, reveals how deeply these diseases affect the lives of individuals and their families.